Similarity assessment by multivariate statistics method based on the distance between biosimilar and originator

Abstract

The development of biosimilar products or follow-on biologics has been flourishing in recent years because of their lower price than the originators. In this study, a multivariate data analysis method based on JMP software was proposed to assess the glycosylation pattern similarity of antibody candidates from different conditions in optimization experiments with a reference. A specific distance was generated by this method and indicated the glycoform similarity between the biosimilar and the reference. This method can be applied to analyze the similarity of other physicochemical and functional characteristics between follow-on biologics and originators. Then, the design of experimental methods can be realized to optimize the conditions of cell culture to attain similar antibody candidates. A higher concentration of GlcNAc added to the basal media made the glycan of the antibody more similar to the glycan of the reference in this study.

Keywords

Biosimilar / Cluster analysis / Glycosylation pattern / Multivariate statistics method / Similarity

References

[1] Andreas A, Margareta A, Naomi CB. To cluster, or not to cluster: An analysis of clusterability methods. Pattern Recogn, 2019, 88: 13-26.

[2] Burchiel SW, Aspbury R, Munday J. The search for biosimilars and biobetters. Drug Discovery Today, 2019, 24(5): 1087-1091.

[3] Crowell CK, Grampp GE, Rogers GN, Miller J, Scheinman RI. Amino acid and manganese supplementation modulates the glycosylation state of erythropoietin in a CHO culture system. Biotechnol Bioeng, 2007, 96(3): 538-549.

[4] EMA (2015) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf

[5] FDA (2015) Guidance for industry: Scientific considerations in demonstrating biosimilarity to a reference product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf

[6] Gramer MJ, Eckblad JJ, Donahue R, Brown J, Shultz C, Vickerman K, Priem P, Bremer E, Gerritsen J, Berkel P. Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose. Biotechnol Bioeng, 2011, 108(7): 1591-1602.

[7] Kang SH, Chow SC. Statistical assessment of biosimilarity based on relative distance between follow-on biologics. Statist Med, 2013, 32(3): 382-392.

[8] Kirchhoff CF, Wang XZM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng, 2017, 114(12): 2696-2705.

[9] Linming L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci, 2015, 104(6): 1866-1884.

[10] Patrick H, Khattak SF, Li ZJ. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology, 2009, 19(9): 936-949.

[11] WHO (2016) Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs). https://www.who.int/biologicals/biotherapeutics/WHO_TRS_1004_web_Annex_2.pdf